Develops precision radiopharmaceuticals that target cancer cells using radioactive isotopes, enabling localized treatment while minimizing damage to surrounding healthy tissue. This approach addresses the limitations of conventional therapies by improving treatment efficacy and reducing systemic side effects for patients with various cancer types.
Funding
$248.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DTFCFounders
Product
Problem
Conventional cancer treatments often lack precision, leading to damage of healthy tissues surrounding the tumor and resulting in significant systemic side effects for patients. This lack of targeted delivery limits treatment efficacy and impacts the patient's quality of life during and after therapy.
Solution
Mariana Oncology, a Novartis company, is developing precision radioligand therapies (RLTs) designed to selectively target and destroy cancer cells while minimizing harm to healthy tissue. Their approach involves identifying novel targets within tumors, even those that are immunologically silent and challenging to treat with traditional methods. By using radioactive isotopes attached to targeting molecules, Mariana Oncology aims to deliver localized radiation directly to cancer cells, improving treatment efficacy and reducing systemic toxicity. The company is advancing a pipeline of targeted RLT candidates with the potential to address a broad range of cancers, with the goal of optimizing efficacy and allowing patients to live better during their treatment journey.
Target Audience
The primary target audience includes patients with various cancer types, as well as oncologists and medical professionals seeking more precise and effective cancer treatment options with improved patient outcomes.
Features
- Development of novel radioligand therapies (RLTs) for precision cancer treatment
- Focus on identifying overlooked targets in immunologically silent and radiosensitive tumors
- Targeted delivery of radioactive isotopes directly to cancer cells
- Pipeline of RLT candidates designed to address a broad range of cancers
- Aims to improve treatment efficacy and reduce systemic side effects compared to conventional therapies